Bio-Rad is at the forefront of antibody development, leveraging cutting-edge technologies and expertise to address critical challenges in the field. Bio-Rad’s antibody services including HuCAL TM ...

The review of phage display technology highlights various strategies for improving antibody selection ... The first nanobody-based drug, Caplacizumab, was approved in 2018, and ongoing clinical ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® ...

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published ... used in combination ...

NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...

In this Review, we summarise common mechanisms driving acute and ... With the increasing use of radiotherapy in the setting of multimodal therapy (which includes immunotherapy, drug-antibody ...

Peter Horby, co-lead of the trial told Nature Review Drug Discovery: “It’s very clear that there’s been a huge amount of wasted resource, on multiple underpowered or poorly designed trials. That’s ...

With the advent of artificial intelligence (AI), the industry witnessed a rapid transformation in early disease detection, genomic research, drug discovery, clinical processes, and treatment ...

With the advent of artificial intelligence (AI), the industry witnessed a rapid transformation in early disease detection, genomic research, drug discovery, clinical processes, and treatment efficacy ...